$Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity$

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity

Abstract Background The management of ultracentral thoracic tumors with ablative dose of radiotherapy remains challenging given proximity to critical central structures. We report patient outcomes, toxicity, and dosimetry for ultracentrally located tumors with hypofractionated stereotactic body radi...

Full description

Bibliographic Details
Main Authors:	Crosby Rock, Sumit Sood, Ying Cao, Shary Shelton, Ronald C. Chen, Fen Wang
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	Radiation Oncology
Subjects:	Ultracentral Hypofractionated Stereotactic body radiotherapy Lung
Online Access:	https://doi.org/10.1186/s13014-023-02298-1

Similar Items

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
by: Maria L. Sandoval, MD, MS, et al.
Published: (2023-05-01)

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
by: Ishita Chen, et al.
Published: (2023-01-01)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
by: Jiang Xue-song, et al.
Published: (2012-03-01)

Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation
by: Laurence Mengue, et al.
Published: (2020-04-01)

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
by: Dan Yang, et al.
Published: (2020-03-01)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
by: Tyler Gutschenritter, et al.
Published: (2020-12-01)

Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
by: Xue-Yi Xie, et al.
Published: (2022-07-01)

Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors
by: Alonso La Rosa, et al.
Published: (2024-01-01)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
by: Christine Kornhuber, et al.
Published: (2023-05-01)

Clinical outcomes of Hypofractionated stereotactic radiotherapy (HFSRT) among patients with brain metastases in a tertiary medical center in the Philippines
by: Jo-Celine Leong, et al.
Published: (2022-12-01)

Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis
by: Conti Alfredo, et al.
Published: (2019-11-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
by: Sebastian Regnery, et al.
Published: (2020-10-01)

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk
by: Marcin Miszczyk, et al.
Published: (2022-09-01)

Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
by: Yun Guan, et al.
Published: (2022-04-01)

Dosimetric Parameters in Hypofractionated Stereotactic Radiotherapy for Brain Metastases: Do Flattening Filter-Free Beams Bring Benefits? A Preliminary Study
by: Diana M. Ghemiș, et al.
Published: (2023-01-01)

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol
by: Yun Guan, et al.
Published: (2022-07-01)

Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses
by: Cecilia Jiang, et al.
Published: (2023-11-01)

A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients
by: Silvia Takanen, et al.
Published: (2022-10-01)

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer
by: Katrina Woodford, et al.
Published: (2017-10-01)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
by: Maria Chiara Lo Greco, et al.
Published: (2023-06-01)

Cellular bases of hypofractionated radiotherapy protocols for lung cancer
by: ELIANA EVELINA OCOLOTOBICHE, et al.
Published: (2022-07-01)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
by: Huayong Jiang, et al.
Published: (2021-12-01)

Effect of stereotactic radiotherapy on immune microenvironment of lung cancer
by: Yao Xiao, et al.
Published: (2022-09-01)

Hypofractionated radiotherapy and stereotactic boost with concurrent and adjuvant temozolamide for glioblastoma in good performance status elderly patients – early results of a phase II trial.
by: Scott eFloyd, et al.
Published: (2012-10-01)

A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial
by: Julian Biau, et al.
Published: (2020-08-01)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
by: Ju Andrew W, et al.
Published: (2013-01-01)

Five-Fraction Stereotactic Radiotherapy for Brain Metastases—A Retrospective Analysis
by: Julian P. Layer, et al.
Published: (2023-01-01)

Efficacy and Toxicity of Hypofractionated Palliative Radiotherapy for Breast Cancer Patients with Skin Invasion
by: Talha Maqsood, et al.
Published: (2023-08-01)

Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond
by: Febin Antony, et al.
Published: (2024-01-01)

Macular hole and vitreous hemorrhage subsequent to stereotactic hypofractionated radiotherapy for choroidal melanoma: A case report and review of the literature
by: Xiaoyin Zhou, et al.
Published: (2022-11-01)

Hypofractionated Radiotherapy in African Cancer Centers
by: William Swanson, et al.
Published: (2021-02-01)

Hypofractionated Radiation Therapy for Large Brain Metastases
by: Giuseppina Laura Masucci
Published: (2018-10-01)

Conventional versus different hypofractionated radiotherapy dosage schedules in postmastectomy advanced breast cancer
by: Neeraj Jain, et al.
Published: (2022-01-01)

Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases
by: Geoffrey Martinage, et al.
Published: (2019-03-01)

Hypofractionated Radiotherapy for Post-Operative Breast Cancer Patients at Delta Hospital - an Evaluation of Clinical Experience
by: Parvin Akhter Banu, et al.
Published: (2015-01-01)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
by: Sean Mahase, et al.
Published: (2020-12-01)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
by: Dong-Yun Kim, et al.
Published: (2021-02-01)

Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome
by: Barra S, et al.
Published: (2018-03-01)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
by: Georges Noël, et al.
Published: (2013-09-01)